X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 54 filers reported holding X4 PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,056 | -91.7% | 49,593 | -85.2% | 0.00% | – |
| Q2 2023 | $648,816 | +793.3% | 334,441 | +300.6% | 0.00% | – |
| Q1 2023 | $72,629 | +33.0% | 83,482 | +51.8% | 0.00% | – |
| Q4 2022 | $54,595 | -42.5% | 54,980 | -0.7% | 0.00% | – |
| Q3 2022 | $95,000 | +97.9% | 55,380 | +164.4% | 0.00% | – |
| Q4 2021 | $48,000 | -12.7% | 20,949 | +100.0% | 0.00% | – |
| Q3 2021 | $55,000 | -84.3% | 10,475 | -80.6% | 0.00% | – |
| Q2 2021 | $351,000 | -50.9% | 54,007 | -35.0% | 0.00% | – |
| Q1 2021 | $715,000 | +98.6% | 83,037 | +48.3% | 0.00% | – |
| Q4 2020 | $360,000 | +3.4% | 56,006 | +8.9% | 0.00% | – |
| Q3 2020 | $348,000 | +18.4% | 51,418 | +62.8% | 0.00% | – |
| Q2 2020 | $294,000 | +107.0% | 31,583 | +123.2% | 0.00% | – |
| Q1 2020 | $142,000 | -30.7% | 14,150 | -26.0% | 0.00% | – |
| Q4 2019 | $205,000 | +8.5% | 19,125 | +28.8% | 0.00% | – |
| Q3 2019 | $189,000 | -60.6% | 14,845 | -53.6% | 0.00% | – |
| Q2 2019 | $480,000 | – | 32,025 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 12,202,510 | $10,616 | 1.33% |
| Tri Locum Partners LP | 3,878,484 | $3,374,281 | 1.03% |
| Lynwood Capital Management Inc. | 900,000 | $783,000 | 0.71% |
| NEA Management Company, LLC | 11,736,793 | $10,211,010 | 0.71% |
| Parkman Healthcare Partners LLC | 2,797,147 | $2,433,518 | 0.53% |
| SCOGGIN MANAGEMENT LP | 484,796 | $567,025 | 0.33% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $291,450 | 0.24% |
| Ghost Tree Capital, LLC | 850,000 | $740,000 | 0.22% |
| Perceptive Advisors | 4,545,454 | $3,954,545 | 0.12% |
| Orbimed Advisors | 5,817,726 | $5,061,422 | 0.10% |